MedTrace Logo

Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain

NCT01851499 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2015-10-20

No results posted yet for this study

Summary

Randomized, double-blinded, placebo-controlled, parallel group study of ultramicronized PEA (Normast)600 mg x 2 daily or corresponding placebo with a week of baseline period followed by 1 x 12 weeks treatment period.

Conditions

  • Neuropathic Pain
  • Spinal Cord Injury

Interventions

DIETARY_SUPPLEMENT

Ultramicronized PEA (Normast)

600 mg

Sponsors & Collaborators

  • Spinal Cord Injury Centre of Western Denmark

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • Epitech Group SRL, Italy

    collaborator UNKNOWN

  • Danish Pain Research Center

    lead OTHER

Principal Investigators

  • Sven R. Andresen, MD · Spinal Cord Injury Centre of Western Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-05-31
Completion
2015-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01851499 on ClinicalTrials.gov